Current Report · Items 2.02, 7.01, 9.01 · 8-K
Masimo Corporation
Results of Operations and Financial Condition · Regulation FD Disclosure
Item 2.02. Results of Operations and Financial Condition. On January 12, 2026, Masimo Corporation (the “Company”) issued a press release announcing select preliminary financial results for the fourth quarter and full-year ended January 3, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.…
Filed Jan 12, 2026Accepted Jan 12, 2026, 9:02 AM ESTCIK 937556Accession 0000937556-26-000005
Company context
Masimo (Nasdaq: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve life, improve patient outcomes, reduce the cost of care, and take noninvasive monitoring to new sites and applications. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown to outperform other pulse oximetry technologies in over 100 independent and objective studies, which can be found at www.masimo.com/evidence/featured-studies/feature. Masimo SET® is estimated to be used on more than 200 million patients around the world each year and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2025 Newsweek World’s Best Hospitals listing. Additional information about Masimo and its products may be found at www.masimo.com.
Historical securities (1)
Disclosure sections
Items 2.02, 7.01, 9.01Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 2.02Item 2.02 - Results of Operations
Item 2.02. Results of Operations and Financial Condition.
On January 12, 2026, Masimo Corporation (the “Company”) issued a press release announcing select preliminary financial results for the fourth quarter and full-year ended January 3, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report. The preliminary financial information presented in this press release is based on the Company’s current expectations and may be adjusted as a result of, among other things, completion of customary annual audit procedures. The Company’s management plans to discuss the Company’s complete fourth quarter and full-year 2025 financial results after the market closes on Thursday, February 26, 2026.
In accordance with General Instructions B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
In connection with the Company’s participation at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, the Company’s Chief Executive Officer and EVP, Chief Financial Officer, will review select preliminary financial results for the fourth quarter and full-year 2025.
In addition, the Company is making available to investors supplemental financial information for fiscal 2025, as well as a discussion of non-GAAP measures, adjustments and definitions pursuant to the materials furnished as Exhibit 99.2 to this Current Report.
In accordance with General Instructions B.2 of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 (by filename) masi-20260112x8kxex991.htmEX-99.1
2
masi-20260112x8kxex991.htm
EX-99.1
Document
Exhibit 99.1
Masimo Announces Select Preliminary 2025 Financial Results
Complete fourth quarter and full-year 2025 financial results will be announced on Thursday, February 26, 2026
Irvine, California, January 12, 2026 - Masimo Corporation (Nasdaq: MASI) today announced select preliminary financial results for the fourth quarter and full-year ended January 3, 2026.
Preliminary Fourth Quarter 2025 Financial Results:
Revenue is expected to be approximately $411 million, representing approximately 12% growth on a reported basis and 11% growth on a constant currency basis(1);
Non-GAAP earnings per diluted share(2), including the impact of new tariffs, are expected to be more than $1.54; and
Shipments of noninvasive technology boards and instruments are expected to be approximately 69 thousand.
Preliminary Full-Year 2025 Financial Results:
Revenue is expected to be approximately $1,523 million, representing approximately 9% growth on a reported basis and constant currency basis(1);
Non-GAAP earnings per diluted share(2), including the impact of new tariffs, are expected to be more than $5.55, which represents th…
Open exhibit ↗